PharmaCielo Ltd. (TSXV:PCLO)
Canada · Delayed Price · Currency is CAD 0.0650
-0.0100 (-13.33%)
Aug 10, 2026, 3:59 PM EST
PharmaCielo Balance Sheet
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.02 | 0.05 | 0.06 | 0.17 | 5.34 |
Short-Term Investments | - | - | - | 0.15 | 0.29 |
Cash & Short-Term Investments | 0.02 | 0.05 | 0.06 | 0.33 | 5.63 |
Cash Growth | -67.63% | -12.98% | -80.93% | -94.21% | -36.97% |
Accounts Receivable | 0.31 | 0.47 | 0.23 | 0.61 | 0.28 |
Inventory | 1.96 | 1.37 | 2.31 | 2.13 | 2.28 |
Other Current Assets | 1.26 | 0.52 | 0.72 | 0.95 | 1.01 |
Total Current Assets | 3.56 | 2.41 | 3.33 | 4.02 | 9.2 |
Net Property, Plant & Equipment | 9.01 | 16.12 | 18.71 | 20.62 | 26.12 |
Long-Term Investments | - | - | 0.21 | 0.2 | 0.64 |
Other Long-Term Assets | - | - | 0.04 | 0.27 | - |
Total Assets | 12.57 | 18.53 | 22.29 | 25.12 | 35.96 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.37 | 5.76 | 5.63 | 6.11 | 7.73 |
Current Portion of Long-Term Debt | 18.16 | 17.61 | 15.71 | 0.55 | 0.08 |
Current Portion of Leases | - | - | 0.04 | 0.27 | 0.15 |
Other Current Liabilities | 0.03 | 0.03 | 0.03 | 0.03 | 0.11 |
Total Current Liabilities | 23.55 | 23.4 | 21.42 | 6.95 | 8.07 |
Long-Term Debt | - | 4.62 | 2.55 | 11.73 | 7.14 |
Long-Term Leases | - | - | - | 0.04 | 1.06 |
Other Long-Term Liabilities | - | - | - | - | 0.36 |
Total Long-Term Liabilities | - | 4.62 | 2.55 | 11.77 | 8.56 |
Total Liabilities | 23.55 | 28.02 | 23.97 | 18.72 | 16.63 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 169.12 | 168.15 | 165.98 | 161.71 | 156.34 |
Additional Paid-in Capital | 38.16 | 38.04 | 36.41 | 35.79 | 37.09 |
Accumulated Other Comprehensive Income | -4.61 | -5.61 | -5.36 | -8.69 | -6.21 |
Retained Earnings | -213.66 | -210.08 | -198.71 | -182.41 | -167.9 |
Shareholders' Equity | -10.98 | -9.49 | -1.68 | 6.39 | 19.33 |
Total Liabilities & Equity | 12.57 | 18.53 | 22.29 | 25.12 | 35.96 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 18.16 | 22.23 | 18.31 | 12.59 | 8.43 |
Net Cash (Debt) | -18.14 | -22.18 | -18.25 | -12.26 | -2.8 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.10 | -0.13 | -0.11 | -0.08 | -0.02 |
Book Value | -10.98 | -9.49 | -1.68 | 6.39 | 19.33 |
Book Value Per Share | -0.06 | -0.05 | -0.01 | 0.04 | 0.13 |
Tangible Book Value | -10.98 | -9.49 | -1.68 | 6.39 | 19.33 |
Tangible Book Value Per Share | -0.06 | -0.05 | -0.01 | 0.04 | 0.13 |